These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 35995401)

  • 1. Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
    Park JM; Peng JM; Shen YS; Lin CY; Hsu TW; Su YH; Chen HA; Saengboonmee C; Chang JS; Chiu CF; Shan YS
    Mol Metab; 2022 Nov; 65():101576. PubMed ID: 35995401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
    Su YH; Hsu TW; Chen HA; Su CM; Huang MT; Chuang TH; Leo Su J; Hsieh CL; Chiu CF
    J Cell Physiol; 2021 Jun; 236(6):4420-4434. PubMed ID: 33184874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Palam LR; Gore J; Craven KE; Wilson JL; Korc M
    Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
    Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y
    Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
    Dash S; Ueda T; Komuro A; Amano H; Honda M; Kawazu M; Okada H
    Mol Cancer Res; 2023 May; 21(5):444-457. PubMed ID: 36757299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma.
    Sun H; Ge Y; Liu J; Li Z; Li H; Zhao T; Wang X; Feng Y; Wang H; Gao S; Shi L; Yang S; Sun P; Chang A; Hao J; Huang C
    Oncogene; 2024 Mar; 43(11):776-788. PubMed ID: 38243080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism.
    Fujiwara-Tani R; Sasaki T; Takagi T; Mori S; Kishi S; Nishiguchi Y; Ohmori H; Fujii K; Kuniyasu H
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
    Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
    Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
    Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
    Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
    Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
    PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
    Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
    Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
    Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
    Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.